TEVETEN HCT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Teveten Hct, and when can generic versions of Teveten Hct launch?
Teveten Hct is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.
Summary for TEVETEN HCT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Clinical Trials: | 3 |
| Patent Applications: | 8 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in TEVETEN HCT? | TEVETEN HCT excipients list |
| DailyMed Link: | TEVETEN HCT at DailyMed |
Recent Clinical Trials for TEVETEN HCT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Quintiles, Inc. | Phase 3 |
| Abbott | Phase 3 |
| author! et al. BV | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for TEVETEN HCT
US Patents and Regulatory Information for TEVETEN HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEVETEN HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TEVETEN HCT
See the table below for patents covering TEVETEN HCT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 2232 | Imidazolyl-alkenoic acids | ⤷ Try a Trial |
| Luxembourg | 90562 | ⤷ Try a Trial | |
| Hungary | 903846 | ⤷ Try a Trial | |
| New Zealand | 233996 | IMIDAZOLYL-ALKENOIC ACID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | ⤷ Try a Trial |
| Philippines | 26976 | Imidazolyl-alkenoic acids and their method of use | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TEVETEN HCT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0403159 | C300006 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417 |
| 0565634 | 300115 | Netherlands | ⤷ Try a Trial | |
| 0565634 | 91234 | Luxembourg | ⤷ Try a Trial | 91234, EXPIRES: 20161213 |
| 0403159 | SPC/GB00/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EPROSARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING EPROSARTAN MESYLATE; REGISTERED: DE 39 573.00.00 19970417; DE 39 573.01.00 19970417; DE 39 573.02.00 19970417; UK PL00512/0162 19990823; UK PL00512/0163 19990823; UK PL00512/0164 19990823 |
| 0565634 | C300115 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EPROSARTANUM DESGEWENST IN DE VORM VAN EEN; NAT. REGISTRATION NO/DATE: RVG 25926 20020905; FIRST REGISTRATION: RVG 25926 20020905 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
